Want to see JP:4521 full AI Analyst Report?
Kaken Pharmaceutical Co (4521) AI Stock Analysis
Kaken Pharmaceutical Co
(TSE/TYO:4521)
The score is held back primarily by weakened recent financial performance and negative operating/free cash flow, partially offset by a very conservative balance sheet. Technical indicators show positive momentum, and valuation is supported by a moderate P/E and strong dividend yield.
Kaken Pharmaceutical Co (4521) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 984.58M
- Dividend Yield
- 4.88%
- Average Volume (3M)
- 120.05K
- Price to Earnings (P/E)
- 13.9
- Beta (1Y)
- 0.31
- Revenue Growth
- -6.86%
- EPS Growth
- -17.71%
- Country
- Japan
- Employees
- 1,114
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Kaken Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product por...
How the Company Makes Money
Kaken Pharmaceutical primarily makes money by selling prescription pharmaceuticals in Japan. Its core revenue model is to (1) develop or in-license drug candidates, (2) obtain regulatory approvals, and (3) commercialize approved products as branded p...
Kaken Pharmaceutical Co Financial Statement Overview
Summary
Mixed fundamentals: a very strong, low-leverage balance sheet (Debt/Equity ~0.03) is a major support, but the latest year showed a sharp operational setback (revenue -18.8%, operating profit turned slightly negative) and cash flow deterioration (negative operating and free cash flow), which lowers confidence in near-term earnings quality.
Income Statement
44NeutralBalance Sheet
86Very PositiveCash Flow
32Negative| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.65B | 94.03B | 76.87B | 72.04B | 72.98B | 76.03B |
| Gross Profit | 58.08B | 58.26B | 39.24B | 38.54B | 39.56B | 41.58B |
| EBITDA | 20.31B | 22.02B | 5.68B | 12.57B | 9.40B | 16.38B |
| Net Income | 12.46B | 13.95B | 2.14B | 8.03B | 5.44B | 9.55B |
Balance Sheet | ||||||
| Total Assets | 176.34B | 190.42B | 178.22B | 171.62B | 166.33B | 165.18B |
| Cash, Cash Equivalents and Short-Term Investments | 55.40B | 70.08B | 50.70B | 65.32B | 74.26B | 74.62B |
| Total Debt | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B |
| Total Liabilities | 28.89B | 37.78B | 30.59B | 27.87B | 29.49B | 26.85B |
| Stockholders Equity | 147.45B | 152.63B | 147.62B | 143.75B | 136.26B | 137.75B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 25.64B | -14.07B | 716.00M | 7.27B | 10.35B |
| Operating Cash Flow | 0 | 29.78B | -11.08B | 2.58B | 9.25B | 13.34B |
| Investing Cash Flow | 0 | -19.65B | 315.00M | -5.85B | -2.63B | -7.89B |
| Financing Cash Flow | 0 | -5.37B | -8.84B | -5.66B | -6.99B | -8.13B |
Kaken Pharmaceutical Co Peers Comparison
Overall Rating
JP:453468Neutral
JP:454764Neutral- JP:452163Neutral
JP:455360Neutral
JP:456952Neutral
JP:488752Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4534 | 68Neutral | JPY 111.44B | 12.54 | 6.64% | 2.43% | 14.72% | 52.55% |
| JP:4547 | 64Neutral | JPY 153.38B | 13.78 | 4.95% | 5.30% | 5.87% | -21.24% |
| JP:4521 | 63Neutral | JPY 136.15B | 13.90 | 6.94% | 4.88% | -6.86% | -17.71% |
| JP:4553 | 60Neutral | JPY 172.99B | 20.24 | 4.53% | 2.19% | 6.78% | -48.34% |
| JP:4569 | 52Neutral | JPY 57.80B | 29.55 | ― | 4.09% | -4.71% | -78.91% |
| JP:4887 | 52Neutral | JPY 167.94B | 22.02 | ― | 3.23% | 11.08% | 701.86% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4521 | Kaken Pharmaceutical Co | 3890.00 | 379.47 | 10.81% | |
| JP:4547 | Kissei Pharmaceutical Co | 3870.00 | 40.60 | 1.06% | |
| JP:4553 | Towa Pharmaceutical Co | 3650.00 | 919.45 | 33.67% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3395.00 | 378.34 | 12.54% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1149.00 | -213.93 | -15.70% | |
| JP:4887 | SAWAI GROUP HOLDINGS Co., Ltd. | 1736.00 | -76.62 | -4.23% |
Kaken Pharmaceutical Co Corporate Events
Kaken Pharmaceutical Swings to Strong Profit but Suspends Dividend Despite Sales Surge
Kaken Pharmaceutical reported strong top-line growth for the three months ended June 30, 2026, with net sales climbing 59.8% year on year to ¥30.15 billion and profit attributable to owners of the parent surging to ¥8.44 billion, boosting b...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026